BDX price target lowered

What happened: On April 14, RBC Capital lowered its price target on Becton, Dickinson and Company (BDX) to $175 from $195, maintaining a Sector Perform rating. Despite stable medtech demand, RBC cited valuation concerns. In contrast, BDX was recently included among the top 10 healthcare stocks with the highest dividends. Meanwhile, BDX uplifted its FY26 revenue outlook based on steady portfolio performance, reporting a 5.2% YoY increase in Q2 2026 revenues.

Market impact: The price target reductions by RBC and Argus (to $180) suggest a potential repricing of BDX's valuation, affecting investors seeking high dividend yields. However, BDX's bullish outlook on FY26 revenues indicates continued demand for its medical supplies and devices, benefiting the broader medtech sector.

What to watch next: BDX's upcoming earnings release (scheduled, but date not specified in the provided articles) will provide further clarity on its financial performance and outlook. Additionally, any updates to BDX's dividend policy or guidance on its transition towards a pure-play medtech company will be crucial for investors.